We focus on the relationships between schizophrenia and religiosity, on the basis of the review of literature and the data of an ongoing study about religiousness and personality, and religious coping conducted among outpatients with schizophrenia. Religion may be part of the psychopathology, but some of its dimensions may be protective from the negative effects of the illness. Religion may be relevant for the treatment of people with schizophrenia in that it may help to reduce pathology, to enhance coping and to foster recovery. Religiosity is multidimensional concept and so it must be evaluated in the people with schizophrenia (Aukst-Margetic et al. 2005).
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effectiveness and safety of aripiprazole oral solution in the acute treatment of schizophrenia in Chinese patients.
BMC Psychiatry
December 2024
The National Clinical Research Center for Mental Disorders, Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, 100088, China.
Background: This study investigates the effectiveness and safety of aripiprazole oral solution in Chinese patients with schizophrenia.
Methods: This was a multicenter, single-arm phase IV study involving 134 patients in China in the acute stage of schizophrenia from May 2021 to July 2022. The patients received aripiprazole oral solution 10 - 30 mg/d for 12 weeks.
Improving the physical health of overweight/obese people suffering from severe mental disorders: What is the role of antipsychotic drugs and of lifestyle psychosocial interventions?
J Psychiatr Res
November 2024
Department of Psychiatry, University of Campania "Vanvitelli", Italy.
People with severe mental disorders experience premature mortality compared with the general population. Several factors contribute to the mortality gap, including the adoption of unhealthy lifestyle behaviours, poor screening for physical illnesses, difficulties in accessing healthcare facilities, specific clinical features of mental disorders and some pharmacological treatment such as antipsychotic medications with serious metabolic side effects. In the present study, carried out in the framework of the LIFESTYLE trial, a funded nationwide multicentric study, we aimed to assess the impact of different antipsychotics in mediating the effectiveness of psychosocial intervention on healthy lifestyle behaviours.
View Article and Find Full Text PDFUncovering metabolic dysregulation in schizophrenia and cannabis use disorder through untargeted plasma lipidomics.
Sci Rep
December 2024
Department of Pharmacology, University of the Basque Country, UPV/EHU, Sarriena S/N, 48940, Leioa, Bizkaia, Spain.
Cannabis use disorder affects up to 42% of individuals with schizophrenia, correlating with earlier onset, increased positive symptoms, and more frequent hospitalizations. This study employed an untargeted lipidomics approach to identify biomarkers in plasma samples from subjects with schizophrenia, cannabis use disorder, or both (dual diagnosis), aiming to elucidate the metabolic underpinnings of cannabis abuse and schizophrenia development. The use of liquid chromatography-high resolution mass spectrometry enabled the annotation of 119 metabolites, with the highest identification confidence level achieved for 16 compounds.
View Article and Find Full Text PDFEffectiveness of a social cognition remediation intervention for patients with schizophrenia: a randomized-controlled study.
Ann Gen Psychiatry
December 2024
University of Campania "Luigi Vanvitelli", Piazza Miraglia 2, 80138, Naples, Italy.
This randomized-controlled study evaluates the effectiveness of a newly developed social cognition rehabilitation intervention, the modified Social Cognition Individualized Activity Lab (mSoCIAL), in improving social cognition and clinical and functional outcomes of persons with schizophrenia recruited in two Italian sites: University of Campania "Luigi Vanvitelli" in Naples and ASST Fatebenefratelli-Sacco in Milan. mSoCIAL consists of a social cognitive training module focusing on different domains of social cognition and of a narrative enhancement module. We assessed changes in social cognition, clinical characteristics and functional variables in patients with schizophrenia who participated in 10 weekly sessions of mSoCIAL or received treatment as usual (TAU).
View Article and Find Full Text PDFCo-designing a low-intensity psychological therapy for fear of recurrence in psychosis using translational learning from fear of recurrence in oncology: protocol for intervention development for future testing in a feasibility study.
BMJ Open
December 2024
School of Health & Wellbeing, University of Glasgow, Glasgow, UK.
Introduction: Fear of recurrence is a transdiagnostic problem experienced by people with psychosis, which is associated with anxiety, depression and risk of future relapse events. Despite this, there is a lack of available psychological interventions for fear of recurrence, and psychological therapies for schizophrenia are often poorly implemented in general. However, low-intensity psychological therapy is available for people who experience fear of recurrence in the context of cancer, which means there is an opportunity to learn what has worked in a well-implemented psychological therapy to see if any learning can be adapted for schizophrenia care.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!